The latest STOPCAP M1 results were presented at American Society of Clinical Oncology (ASCO) Meeting in Chicago, by Dr Claire Vale and Dr Susan Halabi Claire Vale presented results of a meta-analysis of patient data from 2261 men with metastatic hormone sensitive prostate cancer (mHSPC) in 3 trials showed that on average, chemotherapy improved 5-year survival by 11% compare ...